Pacira earnings missed by $0.03, revenue fell short of estimates
Pacira (PCRX) reported Q3 EPS of $0.70, missing estimates by $0.03, with revenue at $176.65M, below the $182.86M consensus. The stock is up 49.43% over 3 months and 65.22% over 12 months. InvestingPro rates its financial health as 'good performance'.
How this was made
The 30-second read
Why it matters
The miss may lead to a short‑term sell‑off, but longer‑term fundamentals could remain intact.
Market read
Earnings miss for a small‑cap biotech; relevant for traders focused on earnings volatility.
What to watch
Potential upside from upcoming product launches or cost‑reduction initiatives not reflected in the earnings release.
Background
Pacira Therapeutics (NASDAQ: PCRX) reported its third‑quarter results, missing both earnings and revenue estimates.
Ticker impact
Q3 earnings miss: EPS $0.70 vs $0.73 estimate and revenue $176.65M vs $182.86M estimate.
likely downside as investors price in weaker results
Both EPS and revenue fell short of consensus, a clear negative catalyst for the stock.
Market effects
May weigh on the broader pain management/medical device sector if peers face similar pressure.
Limited to US small‑cap biotech/healthcare segment.
Low global impact; primarily a company‑specific event.
Counterpoint
If the miss is viewed as a temporary setback and the company has strong pipeline, the dip could be a buying opportunity.
Key entities
- CompanyPacira Therapeutics
US‑listed biotech firm reporting Q3 results.


